Role of Radioembolization for Biliary Tract and Primary Liver Cancer

Taylor, Amy C.; Maddirela, Dilip Rajasekhar; White, Sarah B.

doi:10.1016/j.soc.2019.07.001

Cited by 11 publications

(3 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ideally, liver resection and regional lymphadenectomy are the best treatments, though they are connoted by a recurrence-free survival not higher than 39% 5 years after surgery [ 34 , 35 , 36 ]. Alternatively, systemic chemotherapy and loco-regional therapy such as SIRT do offer a minimal response, with a progression-free survival ranging from 11 to 20 months [ 37 , 38 ].…”

Section: Discussionmentioning

confidence: 99%

Liver Transplantation for Unresectable Intrahepatic Cholangiocarcinoma: The Role of Sequencing Genetic Profiling

Gruttadauria

Barbera

Pagano

et al. 2021

Cancers

View full text Add to dashboard Cite

Intrahepatic cholangiocarcinoma (iCCA) is a rare and aggressive primary liver tumor, characterized by a range of different clinical manifestations and by increasing incidence and mortality rates even after curative treatment with radical resection. In recent years, growing attention has been devoted to this disease and some evidence supports liver transplantation (LT) as an appropriate treatment for intrahepatic cholangiocarcinoma; evolving work has also provided a framework for better understanding the genetic basis of this cancer. The aim of this study was to provide a clinical description of our series of patients complemented with Next-Generation Sequencing genomic profiling. From 1999 to 2021, 12 patients who underwent LT with either iCCA or a combined hepatocellular and cholangiocellular carcinoma (HCC-iCCA) were included in this study. Mutations were observed in gene activating signaling pathways known to be involved with iCCA tumorigenesis (KRAS/MAPK, P53, PI3K-Akt/mTOR, cAMP, WNT, epigenetic regulation and chromatin remodeling). Among several others, a strong association was observed between the Notch pathway and tumor size (point-biserial rhopb = 0.93). Our results are suggestive of the benefit potentially derived from molecular analysis to improve our diagnostic capabilities and to devise new treatment protocols, and eventually ameliorate long-term survival of patients affected by iCCA or HCC-iCCA.

show abstract

Section: Discussionmentioning

confidence: 99%

Liver Transplantation for Unresectable Intrahepatic Cholangiocarcinoma: The Role of Sequencing Genetic Profiling

Gruttadauria

Barbera

Pagano

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Indeed, as described by previous studies, following radioembolization it is reported an increased production of inflammatory cytokines, such as interleukin (IL) 1, IL-6 and IL-8, TNFα, and the release of several inducible factor as hypoxia inducible factor 1α, VEGF, matrix metalloproteinases (MMPs), and mammalian target of rapamycin (mTOR). The combination of SIRT with immune checkpoint inhibitors has demonstrated to enhance the systemic inflammatory response by reverting the suppressive phenotype derived by the upregulation of tumor induced immune checkpoints on peripheral and intratumoral immune cells and stimulating them to produce TNF α and granzyme B that lead to a sustained systemic inflammation and an increased anti-tumor response [ 13 , 71 , 72 ].…”

Section: Combination Of Tare With Immunotherapymentioning

confidence: 99%

SIRT in 2025

Ponziani¹,

Santopaolo²,

Posa

et al. 2022

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

Selective internal radiation therapy represents an endovascular treatment option for patients with primary liver malignancies, in different clinical stages. Potential applications of this treatment are in early-stage hepatocellular carcinoma, as a curative option, or in combination with systemic treatments in intermediate and advanced-stages. This review, based on existing literature and ongoing trials, will focus on the future of this treatment in patients with hepatocellular carcinoma, in combination with systemic treatments, or with the use of new devices and technological developments; it will also describe new potential future indications and structural and organizational perspectives.

show abstract

“…Technological advances in all areas of medicine, especially in recent years, have fundamentally changed the way we treat CCA. While extended liver resections have become possible in terms of surgical therapies, novel local ablation techniques such as selective internal radiotherapy (SIRT) have become available in palliative stages, and improved endoscopic procedures have enabled long-term symptom control [ 1 , 4 , 5 ]. Just recently, combinations of cytotoxic chemotherapy and check-point inhibitors have demonstrated superior tumor control, potentially providing neoadjuvant treatment options enabling long term survival in patients with irresectable disease stages at diagnosis [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Current Trends in Inpatient Care and In-Hospital Mortality of Cholangiocarcinoma in Germany: A Systematic Analysis between 2010 and 2019

Roderburg

Essing

Kehmann

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: Cholangiocarcinoma (CCA) is a rare malignant disease of the biliary tract with an increasing incidence and a high mortality worldwide. Systematic data on epidemiological trends, treatment strategies, and in-hospital mortality of CCA in Germany are largely missing. However, the evaluation and careful interpretation of these data could help to further improve the treatment strategies and outcome of CCA patients in the future. Methods: Standardized hospital discharge data from the German Federal Statistical Office were used to evaluate epidemiological and clinical trends as well as the in-hospital mortality of CCA in Germany between 2010 and 2019. Results: A total of 154,515 hospitalized CCA cases were included into the analyses. The number of cases significantly increased over time (p < 0.001), with intrahepatic CCA (62.5%) being the most prevalent tumor localization. Overall, in-hospital mortality was 11.4% and remained unchanged over time. In-hospital mortality was significantly associated with patients’ age and tumor localization. The presence of clinical complications such as (sub)acute liver failure, acute respiratory distress syndrome (ARDS), or acute renal failure significantly increased in-hospital mortality up to 77.6%. In-hospital mortality was significantly lower among patients treated at high annual case volume centers. Finally, treatment strategies for CCA significantly changed over time and showed decisive differences with respect to the hospitals’ annual case volume. Conclusions: Our data provide a systematic overview on hospitalized CCA patients in Germany. We identified relevant clinical and epidemiological risk factors associated with an increased in-hospital mortality that could help to further improve framework conditions for the management of CCA patients in the future.

show abstract

Role of Radioembolization for Biliary Tract and Primary Liver Cancer

Cited by 11 publications

References 59 publications

Liver Transplantation for Unresectable Intrahepatic Cholangiocarcinoma: The Role of Sequencing Genetic Profiling

Liver Transplantation for Unresectable Intrahepatic Cholangiocarcinoma: The Role of Sequencing Genetic Profiling

SIRT in 2025

Current Trends in Inpatient Care and In-Hospital Mortality of Cholangiocarcinoma in Germany: A Systematic Analysis between 2010 and 2019

Contact Info

Product

Resources

About